Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat.
BACKGROUND
A wealth of clinical and experimental evidence exists for cytomegalovirus (CMV) infection as an accelerating factor in the development of cardiac allograft vasculopathy. In this study, the impact of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) on rat CMV infection-enhanced cardiac allograft vasculopathy is investigated.


RESULTS
Heterotopic rat cardiac allografts were performed from the DA to the WF rat strain, and the recipients were immunosuppressed with cyclosporine A 2 mg.kg-1.d-1 s.c. for a period of 90 days until the end of experiment. Two groups of recipients were infected intraperitoneally with 10(5) plaque-forming units of rat CMV, whereas one group was left noninfected and used as controls. One group of rat CMV-infected rats was treated with DHPG with an initial dose of 20 mg/kg i.p. and a maintenance dose of 10 mg/kg i.p. twice a day from 1 day before transplantation to 30 days after transplantation. Compared with noninfected rats, rat CMV infection was associated with a significant increase in intimal thickening, from 0.68 +/- 0.10 to 1.30 +/- 0.12 score units (P < .01), and double the number of vessels affected (P < .01). DHPG treatment significantly reduced intimal thickening in rat CMV-infected rats, from 1.30 +/- 0.12 to 0.68 +/- 0.13 score units (P < .01), and halved the number of vessels affected (P < .01).


CONCLUSIONS
The present results demonstrate that DHPG prophylaxis entirely abolishes the accelerating effect of rat CMV infection on cardiac allograft vasculopathy in immunosuppressed rat recipients, which is consistent with our earlier findings demonstrating a similar effect in nonimmunosuppressed rat aortic allografts. Taken together, these results suggest that DHPG might be useful in the prevention of CMV-accelerated cardiac allograft vasculopathy among heart transplant recipients.
Lemström
K
K
Transplantation Laboratory, University of Helsinki, Finland. karl.lemstrom@helsinki.fi
Sihvola
R
R
Bruggeman
C
C
Häyry
P
P
Koskinen
P
P
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000517:prevention & control* / Q000821:virology*; D003586:Cytomegalovirus Infections / Q000150:complications* / Q000503:physiopathology; D015774:Ganciclovir / Q000627:therapeutic use*; D006321:Heart / Q000821:virology*; D016027:Heart Transplantation; D051381:Rats; D011919:Rats, Inbred Strains; D011920:Rats, Inbred WF
D000998:Antiviral Agents; D015774:Ganciclovir